Genmab A/S (CPH:GMAB)
1,966.00
-21.50 (-1.08%)
Feb 6, 2026, 11:51 AM CET
Genmab Revenue
Genmab had revenue of $1.02B USD in the quarter ending September 30, 2025, with 23.34% growth. This brings the company's revenue in the last twelve months to $3.85B, up 29.57% year-over-year. In the year 2024, Genmab had annual revenue of $2.99B with 22.32% growth.
Revenue (ttm)
$3.85B
Revenue Growth
+29.57%
P/S Ratio
5.00
Revenue / Employee
$1.43M
Employees
2,681
Market Cap
122.43B DKK
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.99B | 545.24M | 22.32% |
| Dec 31, 2023 | 2.44B | 358.99M | 17.23% |
| Dec 31, 2022 | 2.08B | 796.62M | 61.88% |
| Dec 31, 2021 | 1.29B | -374.23M | -22.52% |
| Dec 31, 2020 | 1.66B | 855.79M | 106.20% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novo Nordisk | 309.06B |
| Coloplast | 27.87B |
| H. Lundbeck | 24.63B |
| Demant | 22.97B |
| GN Store Nord | 16.78B |
| Zealand Pharma | 9.16B |
| Bavarian Nordic | 6.89B |
| Ambu A/S | 6.09B |
Genmab News
- 7 days ago - Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance - Seeking Alpha
- 7 days ago - Grant of Restricted Stock Units and Warrants to Employees in Genmab - GlobeNewsWire
- 8 days ago - Interim Results for the six months ended 31 October 2025 - Benzinga
- 13 days ago - Genmab: Darzalex Growth Fuels Rally, Upside Is Tight - Seeking Alpha
- 15 days ago - Independence Bank of Kentucky Buys 34 Shares of Genmab AS (GMAB) - GuruFocus
- 15 days ago - Genmab Announces 23% Annual Increase In 2025 DARZALEX Sales - Nasdaq
- 15 days ago - Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2025 - GlobeNewsWire
- 16 days ago - Genmab Lymphoma Study Misses Key Target, Analyst Still Sees Upside - Benzinga